DelveInsight’s, “Anti-CD20 antibody – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Anti-CD20 antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Anti-CD20 antibody Understanding
Anti-CD20 antibody: Overview
CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells. This pattern, together with consistent and high levels of expression of CD20 on malignant B-cells, makes CD20 a therapeutic target. CD20 protein consists of four hydrophobic transmembrane domains, one intracellular and two extracellular domains (large and small loops) with both N- and C- termini residing within the cytosol. Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Use of anti-CD20 therapy is vastly practiced to treat diseases with a high expression of CD20 antigen. Anti-CD20 antibodies are one of the most successful and effective antibodies which have employed in treatment of a wide range of diseases including cancer and immune related disorders.
""Anti-CD20 antibody - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD20 antibody pipeline landscape is provided which includes the disease overview and Anti-CD20 antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD20 antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD20 antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD20 antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD20 antibody.
Anti-CD20 antibody Emerging Drugs Chapters
This segment of the Anti-CD20 antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD20 antibody Emerging Drugs
• Ublituximab: TG therapeutics
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. TG Therapeutics completes the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody as a treatment for patients with chronic lymphocytic leukemia (CLL). The U.S. FDA previously granted Fast Track designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with umbralisib for the treatment of CLL.
• Glofitamab: Roche
Glofitamab (also known as RO7082859, RG6026) is an investigational, full-length, CD20- and CD3-targeting T-cell bispecific antibody that is designed to redirect T cells to engage and eliminate malignant B cells. Glofitamab is designed to bind to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies, while simultaneously binding to CD3, a component of the TCR on the surface of T cells. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin is underway in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Further product details are provided in the report……..
Anti-CD20 antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD20 antibody drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Anti-CD20 antibody
There are approx. 20+ key companies which are developing the therapies for Anti-CD20 antibody. The companies which have their Anti-CD20 antibody drug candidates in the most advanced stage, i.e. Preregistration include, TG therapeutics.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Anti-CD20 antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Anti-CD20 antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD20 antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD20 antibody drugs.
Anti-CD20 antibody Report Insights
• Anti-CD20 antibody Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Anti-CD20 antibody Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Anti-CD20 antibody drugs?
• How many Anti-CD20 antibody drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anti-CD20 antibody?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD20 antibody therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anti-CD20 antibody and their status?
• What are the key designations that have been granted to the emerging drugs?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook